Table 3. Patent ductus arteriosus (PDA) treatment strategies according to the birthweight group.
| Treatment | Birthweight (g) | Total (n = 2,254) |
|||
|---|---|---|---|---|---|
| <750 (n=379) |
750-999 (n=511) |
1,000-1,249 (n=593) |
1,250-1,499 (n=771) |
||
| No PDA group | 101 (26.6%) |
181 (35.4%) |
322 (54.3%) |
602 (78.1%) |
1,206 (53.5%) |
| PDA group | 278 (73.4%) |
330 (64.6%) |
271 (45.7%) |
169 (21.9%) |
1,048 (46.5%) |
| PT group | 20 (5.3%) |
16 (3.1%) |
21 (3.5%) |
12 (1.6%) |
69 (3.1%) |
| PST group | 41 (10.8%) |
75 (14.7%) |
55 (9.3%) |
41 (5.3%) |
212 (9.4%) |
| ST group | 138 (36.4%) |
190 (37.2%) |
165 (27.8%) |
103 (13.3%) |
596 (26.4%) |
| CT group | 79 (20.9%) |
49 (9.6%) |
30 (5.1%) |
13 (1.7%) |
171 (7.6%) |
*In multinomial logit model, the odds ratio (OR) of the ratio of CT vs. PT was 3.6 (95% CI 1.45-9.17), OR of the ratio of CT vs. PST was 9.2 (95% CI 2.93-12.66), and the OR of the ratio of CT vs. ST was 4.5 (95% CI 2.39-8.62) in birthweight <750 g group when compared with birthweight 1,250-1,499 g group. P<0.001 in 4 PDA treatment subgroups according to the birthweight by chi-square test. PT, prophylactic treatment; PST, pre-symptomatic treatment; ST, symptomatic treatment; CT, conservative treatment without any intervention; PDA, patent ductus arteriosus; OR, odds ratio.